Assessing the impact of HBV NAT on window period reduction and residual risk (Q36532423)

14 August 2017

1 reference

title

Assessing the impact of HBV NAT on window period reduction and residual risk (English)

1 reference

14 August 2017

2

Michael P Busch

1 reference

14 August 2017

Steven H Kleinman

1

1 reference

14 August 2017

1 May 2006

1 reference

Journal of Clinical Virology

14 August 2017

1 reference

14 August 2017

36 Suppl 1

1 reference

14 August 2017

S23-9

1 reference

Estimated risk of transfusion-transmitted viral infections in Spain

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

International application of the incidence rate/window period model.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

HBV: amplified and back in the blood safety spotlight

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

NAT for HBV and anti-HBc testing increase blood safety

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2806%2980005-3

7 January 2021

10.1016/S1386-6532(06)80005-3

Identifiers

DOI

1 reference

release_j2qvk3eoi5apphy2ap2yhtykgi

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/j2qvk3eoi5apphy2ap2yhtykgi

24 November 2022

mapped directly with Wikidata item

PubMed ID

16831689

1 reference

PubMed ID

16831689